bisoprolol and spironolactone

bisoprolol has been researched along with spironolactone in 30 studies

Research

Studies (30)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (20.00)	29.6817
2010's	21 (70.00)	24.3611
2020's	3 (10.00)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Frick, M; Gouya, G; Hügel, H; Pachinger, O; Pölzl, G; Ulmer, H	1
Cohen-Solal, A; Dietz, R; Eichhorn, E; Erhardt, L; Hobbs, FD; Krum, H; Maggioni, A; McKelvie, RS; McMurray, J; Piña, IL; Soler-Soler, J; Swedberg, K	1
Asseman, P; Bauters, C; Darchis, J; De Groote, P; Ennezat, PV; Gonin, X; Lamblin, N; Lejemtel, T	1
Czupryniak, L; Loba, J; Pawłowski, M; Saryusz-Wolska, M	1
Schröder, S; Strobel, J	1
Azizi, M; Bobrie, G; Boutouyrie, P; Chatellier, G; Frank, M; Laurent, S; Menard, J; Peyrard, S; Plouin, PF	1
Anker, SD; Argiles, JM; Beadle, J; Coats, AJ; Doehner, W; Földes, G; Force, T; Grzesiak, A; Haghikia, A; Hilfiker-Kleiner, D; Hocher, B; Jaisser, F; Kaschina, E; Lal, H; Latouche, C; Morawietz, L; Palus, S; Pötsch, M; Springer, J; Thum, T; Tschirner, A; von Haehling, S; von Websky, K	1
Azizi, M; Bobrie, G; Chatellier, G; Frank, M; Ménard, J; Perdrix, L; Plouin, PF	1
Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, I; McInnes, G; Morant, S; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B	1
Bakris, GL; Sternlicht, H	1
Huynh, K	1
Widimský, J	1
Rosenberg, M; Stephens, E	1
Divisón Garrote, JA; Escobar Cervantes, C	1
Boutari, C; Doumas, M; Imprialos, K; Karagiannis, A; Stavropoulos, K	1
Douma, S; Gavriilaki, E; Gkaliagkousi, E; Triantafyllou, A	1
Dale, A; Goldacre, B; Hartley, P	1
Brown, MJ; MacDonald, TM; Morant, SV; Williams, B	1
Kaysin, A; Mounsey, A	1
Allan, GM; Garrison, S; Turgeon, R	1
Brown, MJ; Caulfield, MJ; Cruickshank, JK; Ford, I; MacDonald, TM; Mackenzie, IS; McInnes, GT; Morant, SV; Padmanabhan, S; Salsbury, J; Sever, P; Webb, DJ; Williams, B	1
Buchneva, NN; Kuzmin, OB; Serdyuk, SV; Zhezha, VV	1
Doumas, M; Imprialos, KP; Kallistratos, MS; Manolis, AJ	1
Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A	1
Koiwa, H; Matsushima, S; Morisaki, H; Morisaki, T; Naya, M; Tsujinaga, S; Yokota, T	1

Reviews

3 review(s) available for bisoprolol and spironolactone

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Three drugs and still hypertensive: what's left? Canadian family physician Medecin de famille canadien, 2016, Volume: 62, Issue:11 Topics: Antihypertensive Agents; Bisoprolol; Blood Pressure; Doxazosin; Drug Therapy, Combination; Humans; Hypertension; Potassium; Spironolactone	2016
Recent advances in understanding and managing resistant/refractory hypertension. F1000Research, 2020, Volume: 9 Topics: Antihypertensive Agents; Bisoprolol; Catheters; Clinical Trials as Topic; Clonidine; Denervation; Doxazosin; Humans; Hypertension; Kidney; Spironolactone	2020

Trials

6 trial(s) available for bisoprolol and spironolactone

Article	Year
Circadian blood pressure variation and antihypertensive medication adjustment in normoalbuminuric type 2 diabetes patients. Kidney & blood pressure research, 2007, Volume: 30, Issue:3 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypertension, Renal; Indapamide; Indoles; Male; Middle Aged; Nitrendipine; Perindopril; Spironolactone	2007
Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. Journal of hypertension, 2012, Volume: 30, Issue:8 Topics: Adolescent; Adult; Aged; Amiloride; Angiotensin-Converting Enzyme Inhibitors; Biological Transport; Bisoprolol; Blood Pressure; Drug Resistance; Drug Therapy, Combination; Female; Furosemide; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Nephrons; Prospective Studies; Ramipril; Renin-Angiotensin System; Spironolactone; Young Adult	2012
Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. Journal of hypertension, 2014, Volume: 32, Issue:10 Topics: Adolescent; Adult; Aged; Aldosterone; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Bisoprolol; Blood Pressure; Blood Pressure Determination; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Hypertension; Hypertrophy, Left Ventricular; Irbesartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Ramipril; Renin; Renin-Angiotensin System; Spironolactone; Tetrazoles; Young Adult	2014
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet (London, England), 2015, Nov-21, Volume: 386, Issue:10008 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; Cross-Over Studies; Double-Blind Method; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome	2015
[PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension]. Vnitrni lekarstvi, 2015, Volume: 61, Issue:12 Topics: Antihypertensive Agents; Bisoprolol; Blood Pressure; Diuretics; Doxazosin; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Spironolactone	2015
PURLs: Resistant hypertension? Time to consider this fourth-line drug. The Journal of family practice, 2016, Volume: 65, Issue:4 Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bisoprolol; Doxazosin; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome	2016

Other Studies

21 other study(ies) available for bisoprolol and spironolactone

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
[Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic]. Wiener klinische Wochenschrift, 2002, Oct-31, Volume: 114, Issue:19-20 Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Austria; Bisoprolol; Captopril; Cardiac Care Facilities; Data Interpretation, Statistical; Diuretics; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Neurotransmitter Agents; Practice Guidelines as Topic; Regression Analysis; Spironolactone; Stroke Volume	2002
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. European journal of heart failure, 2005, Volume: 7, Issue:5 Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzopyrans; Biphenyl Compounds; Bisoprolol; Captopril; Carbazoles; Carvedilol; Drug Therapy, Combination; Enalapril; Ethanolamines; Evidence-Based Medicine; Guideline Adherence; Heart Failure; Humans; Indoles; Lisinopril; Metoprolol; Mineralocorticoid Receptor Antagonists; Nebivolol; Practice Guidelines as Topic; Propanolamines; Ramipril; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan	2005
Delayed recovery of left ventricular systolic dysfunction: ''give time to medical therapy''. Minerva cardioangiologica, 2007, Volume: 55, Issue:3 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Middle Aged; Ramipril; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left	2007
[Postpartum cardiomyopathy]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:22 Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Bisoprolol; Bromocriptine; Cardiomyopathies; Female; Heparin, Low-Molecular-Weight; Humans; Mineralocorticoid Receptor Antagonists; Postpartum Period; Radiography; Ramipril; Risk Factors; Spironolactone; Sulfonamides; Torsemide; Treatment Outcome	2011
Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. European heart journal, 2014, Volume: 35, Issue:14 Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Bisoprolol; Body Composition; Body Weight; Cachexia; Glycogen Synthase Kinase 3; Heart Failure; Imidazolidines; Liver Neoplasms; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Myosin Heavy Chains; Rats; Signal Transduction; Spironolactone; Survival Analysis; Ventricular Dysfunction, Left; Wasting Syndrome	2014
Spironolactone for resistant hypertension--hard to resist? Lancet (London, England), 2015, Nov-21, Volume: 386, Issue:10008 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone	2015
Hypertension: PATHWAY to improving the treatment of drug-resistant hypertension. Nature reviews. Nephrology, 2015, Volume: 11, Issue:11 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone	2015
ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk. Annals of internal medicine, 2016, Feb-16, Volume: 164, Issue:4 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone	2016
[Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension]. Semergen, 2016, Volume: 42, Issue:7 Topics: Antihypertensive Agents; Bisoprolol; Doxazosin; Drug Therapy, Combination; Humans; Hypertension; Spironolactone	2016
PATHWAY-2: spironolactone for resistant hypertension. Lancet (London, England), 2016, Apr-02, Volume: 387, Issue:10026 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone	2016
PATHWAY-2: spironolactone for resistant hypertension. Lancet (London, England), 2016, Apr-02, Volume: 387, Issue:10026 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone	2016
PATHWAY-2: spironolactone for resistant hypertension. Lancet (London, England), 2016, Apr-02, Volume: 387, Issue:10026 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone	2016
PATHWAY-2: spironolactone for resistant hypertension - Authors' reply. Lancet (London, England), 2016, Apr-02, Volume: 387, Issue:10026 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Doxazosin; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone	2016
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. The lancet. Diabetes & endocrinology, 2018, Volume: 6, Issue:6 Topics: Aldosterone; Amiloride; Antihypertensive Agents; Bisoprolol; Blood Pressure; Doxazosin; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Spironolactone	2018
[Uncontrolled Arterial Hypertension: Kidney, Neurohormonal Imbalance, and Approaches to Antihypertensive Drug Therapy]. Kardiologiia, 2019, Dec-11, Volume: 59, Issue:12 Topics: Antihypertensive Agents; Bisoprolol; Humans; Hypertension; Kidney; Spironolactone	2019
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats. Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:9 Topics: Animals; Benzhydryl Compounds; Bisoprolol; Cardiovascular Agents; Chronic Disease; Disease Models, Animal; Exercise Tolerance; Fosinopril; Glucosides; Heart Failure; Male; Myocardial Infarction; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Spironolactone; Ventricular Dysfunction, Left; Ventricular Function, Left	2020
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure. The Canadian journal of cardiology, 2022, Volume: 38, Issue:3 Topics: Acute Disease; Bisoprolol; Cardiomegaly; Cardiomyopathies; Cardiovascular Agents; Echocardiography; Genetic Testing; Heart Failure; Humans; Loeys-Dietz Syndrome; Losartan; Male; Middle Aged; Mutation; Pulmonary Edema; Receptor, Transforming Growth Factor-beta Type I; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left	2022